Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry

Published:2001-09 Issue:3 Volume:7 Page:171-177
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Esteva Francisco J.,Hortobagyi Gabriel N.,Sahin Aysegul A.,Smith Terry L.,Chin Dot Mon,Liang Shang -Ying,Pusztai Lajos,Buzdar Aman U.,Bacus Sarah S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF03032345.pdf

Reference41 articles.

1. Bacus SS, Gudkov AV, Esteva FJ, et al; Expression of erb-B receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Disease 11:63–75, 2000.

2. Schechter AL, Hung MC, Vaidyanathan L, et al; The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976–978, 1985.

3. Dickson RB, Lippman ME; Growth factors in breast cancer. Endocr Rev 16:559–589, 1995.

4. Slamon DJ, Clark GM, Wong SG, et al; Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987.

5. Gasparini G, Gullick WJ, Bevilacqua P, et al; Human breast cancer: prognostic significance of the c-erb B-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686–695, 1992.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany;BMC Cancer;2020-11-11

2. HER family in cancer progression: From discovery to 2020 and beyond;Advances in Cancer Research;2020

3. Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer;Applied Immunohistochemistry & Molecular Morphology;2018-03

4. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial;The Lancet Oncology;2017-07

5. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients;Gastric Cancer;2017-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3